Patent US5192806A successfully refreshed from Google Patents.
US5192806A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of preventing penile tissue degenerative change
Assignee: Roche Diagnostics GmbH
•
Filing: 1991-04-15
•
Granted: 1993-03-09
•
Expires: 2011-04-15
Abstract
Abstract The present invention is concerned with the use of TXA2 receptor antagonists for the preparation of pharmaceutical compositions for the prevention of degenerative changes in penile tissue.
Inventors
- 👤 Johannes Pill
- 👤 Johannes Aufenanger
- 👤 Thomas Konrad
- 👤 Klaus-Peter Junemann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 23:01
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/557; A61K31/185; A61K31/19
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
39 words
A method of preventing or reducing degenerative changes in penile tissue in a patient in need of such prevention or reduction, said method comprising administering to said patient an effective amount of at least one TXA 2 receptor antagonist.
Claim 2
Independent Claim
39 words
A method of preventing or reducing degenerative changes in penile tissue in a patient in need of such prevention or reduction, said method comprising administering to said patient an effective amount of at least one TXA 2 receptor antagonist.
Claim 3
Dependent Claim
15 words
The method of claim 1, wherein the degenerative change is atrophy of the corpus cavernosum.
Claim 4
Dependent Claim
13 words
The method of claim 1, wherein the degenerative change is cell nuclei degeneration.
Claim 5
Dependent Claim
14 words
The method of claim 1, wherein the degenerative change is the breakdown of myofilaments.
Claim 6
Dependent Claim
18 words
The method of claim 1, wherein a cause of the degenerative change is physical, chemical, surgical or pathological.
Claim 7
Dependent Claim
17 words
The method of claim 5, wherein the cause of the degenerative change is nicotine abuse or alcoholism.
Claim 8
Dependent Claim
13 words
The method of claim 1, wherein the TXA 2 receptor antagonist is daltroban.
Claim 9
Dependent Claim
24 words
The method of claim 7, wherein the daltroban is administered to the patient in a daily dosage of about 10 to about 1000 mg.
Claim 10
Dependent Claim
14 words
The method of claim 8, wherein the daily dosage is 100 to 800 mg.
Claim 11
Dependent Claim
22 words
The method of claim 8, wherein the daily dosage is administered in dosages units each containing 100 to 200 mg of daltroban.
Claim 12
Dependent Claim
18 words
The method according to claim 1, wherein said at least one TXA 2 receptor antagonist is administered orally.
Claim 13
Dependent Claim
8 words
The method of claim 1 for treating impotence.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-03-08 | 1996-09-07 | 1997-03-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-03-08 | 2000-09-07 | 2001-03-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-03-08 | 2004-09-07 | 2005-03-09 | $7700.00 | Window Closed / Lapsed |